ACCOUNTS RECEIVABLE	9 Months Ended
Sep. 30, 2026
Receivables [Abstract]
ACCOUNTS RECEIVABLE	ACCOUNTS RECEIVABLE Accounts receivable, net of reserves for prompt pay discounts and expected credit losses, was $107.5 million and $80.1 million at September 30, 2026 and December 31, 2025, respectively. The accounts receivable balance as of December 31, 2025 includes the $25.0 million milestone payment due from Mirum Pharmaceuticals, Inc. (“Mirum”), received in April 2026. The accounts receivable balance as of September 30, 2026 includes the additional $10.0 million milestone payment due from Mirum. See Note 18 for further discussion. The total reserves for both periods were immaterial. The Company's evaluation and accounting for credit losses for the current period included an assessment of our aged trade receivables balances and their underlying credit risk characteristics. Our evaluation of past events, current conditions, and reasonable and supportable forecasts about the future resulted in an expectation of immaterial credit losses.

ACCOUNTS RECEIVABLE

9 Months Ended

Sep. 30, 2026

Accounts receivable, net of reserves for prompt pay discounts and expected credit losses, was $107.5 million and $80.1 million at September 30, 2026 and December 31, 2025, respectively. The accounts receivable balance as of December 31, 2025 includes the $25.0 million milestone payment due from Mirum Pharmaceuticals, Inc. (“Mirum”), received in April 2026. The accounts receivable balance as of September 30, 2026 includes the additional $10.0 million milestone payment due from Mirum. See Note 18 for further discussion. The total reserves for both periods were immaterial.

The Company's evaluation and accounting for credit losses for the current period included an assessment of our aged trade receivables balances and their underlying credit risk characteristics. Our evaluation of past events, current conditions, and reasonable and supportable forecasts about the future resulted in an expectation of immaterial credit losses.